Article Versions Notes

Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts J. A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers. 2021; 13(16):4113. https://doi.org/10.3390/cancers13164113

Uckun, Fatih M., Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul J. Shami, Elizabeth Cull, Christopher R. Cogle, and Justin Watts. 2021. "A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome" Cancers 13, no. 16: 4113. https://doi.org/10.3390/cancers13164113

Uckun, F. M., Lin, T. L., Mims, A. S., Patel, P., Lee, C., Shahidzadeh, A., Shami, P. J., Cull, E., Cogle, C. R., & Watts, J. (2021). A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers, 13(16), 4113. https://doi.org/10.3390/cancers13164113